CN109890838A - 新的pdl2化合物 - Google Patents

新的pdl2化合物 Download PDF

Info

Publication number
CN109890838A
CN109890838A CN201780066920.5A CN201780066920A CN109890838A CN 109890838 A CN109890838 A CN 109890838A CN 201780066920 A CN201780066920 A CN 201780066920A CN 109890838 A CN109890838 A CN 109890838A
Authority
CN
China
Prior art keywords
seq
peptide
amino acid
peptide fragment
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780066920.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of CN109890838A publication Critical patent/CN109890838A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780066920.5A 2016-10-27 2017-10-13 新的pdl2化合物 Pending CN109890838A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16195949.9 2016-10-27
EP16195949 2016-10-27
PCT/EP2017/076179 WO2018077629A1 (en) 2016-10-27 2017-10-13 New pdl2 compounds

Publications (1)

Publication Number Publication Date
CN109890838A true CN109890838A (zh) 2019-06-14

Family

ID=57211335

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780066920.5A Pending CN109890838A (zh) 2016-10-27 2017-10-13 新的pdl2化合物

Country Status (5)

Country Link
US (4) US20200024324A1 (https=)
EP (1) EP3532487A1 (https=)
JP (2) JP7312106B2 (https=)
CN (1) CN109890838A (https=)
WO (1) WO2018077629A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017341112B2 (en) * 2016-10-07 2024-06-27 Io Biotech Aps Immunogenic arginase peptides
JP7312106B2 (ja) 2016-10-27 2023-07-20 アイオー バイオテック エーピーエス 新しいｐｄｌ２化合物
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002587A1 (en) * 2000-06-30 2002-01-10 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
US20090042292A1 (en) * 2007-07-13 2009-02-12 The Johns Hopkins University B7-DC Variants
WO2009024531A1 (en) * 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
US20100055102A1 (en) * 2008-08-25 2010-03-04 Solomon Langermann Compositions of pd-1 antagonists and methods of use
WO2010027827A2 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
WO2015100219A1 (en) * 2013-12-23 2015-07-02 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
WO2016168771A2 (en) * 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
JP7312106B2 (ja) 2016-10-27 2023-07-20 アイオー バイオテック エーピーエス 新しいｐｄｌ２化合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002587A1 (en) * 2000-06-30 2002-01-10 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
US20090042292A1 (en) * 2007-07-13 2009-02-12 The Johns Hopkins University B7-DC Variants
WO2009024531A1 (en) * 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
US20100055102A1 (en) * 2008-08-25 2010-03-04 Solomon Langermann Compositions of pd-1 antagonists and methods of use
WO2010027827A2 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
WO2015100219A1 (en) * 2013-12-23 2015-07-02 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
WO2016168771A2 (en) * 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities

Also Published As

Publication number Publication date
US20200392202A1 (en) 2020-12-17
JP2023109840A (ja) 2023-08-08
JP2020500171A (ja) 2020-01-09
US20200024324A1 (en) 2020-01-23
JP7312106B2 (ja) 2023-07-20
US20230227529A1 (en) 2023-07-20
US12215135B2 (en) 2025-02-04
EP3532487A1 (en) 2019-09-04
US20250236658A1 (en) 2025-07-24
US11447537B2 (en) 2022-09-20
WO2018077629A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
KR101391561B1 (ko) Ｈｌａ-ａ*3303 구속성 ｗｔ1 펩티드, 및 그것을 포함하는 의약 조성물
TWI318630B (en) Wt1 modified peptide
US20250236658A1 (en) Pdl2 compounds
CA3058807A1 (en) Protein antigens and uses thereof
CN109310739A (zh) 新抗原及其使用方法
US20240167013A1 (en) Immunogenic arginase peptides
CN109641936A (zh) 用于癌症疫苗中的pdl1肽
CN113966342A (zh) TGF-β疫苗
ES2510493T3 (es) Epítopos T CD4+ de la Survivina y sus aplicaciones
US20180355015A1 (en) Methods and materials for generating t cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination